Insmed Incorporated is a biopharmaceutical company primarily focused on discovering, developing, and marketing therapeutic solutions for individuals afflicted with severe and rare medical conditions. The company's marketed product, ARIKAYCE, is prescribed to adult patients as part of a multi-drug antibacterial regimen for the treatment of Mycobacterium avium complex lung disease. In its robust development pipeline, Insmed is progressing Brensocatib, an oral, reversible dipeptidyl peptidase 1 inhibitor, which targets bronchiectasis and other diseases mediated by neutrophils.